Over 1.4 million Americans have been diagnosed with inflammatory bowel disease (IBD), and ulcerative colitis (UC) makes up approximately half of those diagnoses. As a disease, UC cycles between periods of remission and flare, which is characterized by intense abdominal pain, increased weight loss, intestinal inflammation, rectal bleeding, and dehydration. Interestingly, a widespread recommendation to IBD patients for avoidance of a flare period is "Don't Drink Alcohol" as recent work correlated alcohol consumption with increased GI symptoms in patients with IBD. Alcohol alone not only induces a systemic pro-inflammatory response, but can also be directly harmful to gut barrier integrity. However, how alcohol could result in the exacerbation of UC in both patients and murine models of colitis has yet to be elucidated. Therefore, we conducted a retrospective analysis of patients admitted for IBD with a documented history of alcohol use in conjunction with a newly developed mouse model of binge alcohol consumption following dextran sulfate sodium (DSS)-induced colitis. We found that alcohol negatively impacts clinical outcomes of patients with IBD, specifically increased intestinal infections, antibiotic injections, abdomen CT scans, and large intestine biopsies. Furthermore, in our mouse model of binge alcohol consumption following an induced colitis flare, we found alcohol exacerbates weight loss, clinical scores, colonic shortening and inflammation, and propensity to infection. These findings highlight alcohol's ability to potentiate symptoms and susceptibility to infection in UC and suggest alcohol as an underlying factor in perpetuating symptoms of IBD.
INTRODUCTION
Inflammatory bowel disease (IBD) is diagnosed in over 1.4 million Americans each year. Yet, the exact mechanisms behind disease onset remain elusive. [1] [2] [3] IBD is subdivided into two clinical categories of system with a break in tolerance to commensal intestinal bacteria, environmental factors resulting in dysbiosis of the bacterial population residing in the gut, or some combination thereof that could potentially be contributing to disease onset. As there is no cure for UC, patients are forced into maintenance regimens obtaining symptomatic relief through the use of immunosuppressive drugs, antibiotics, or surgical therapies. 2, [6] [7] [8] Although these treatments aid in relieving symptoms of UC, the resulting immunosuppression could allow for the invasion of pathogenic bacteria that would have normally been defended against. Furthermore, changes in bacterial populations from antibiotic treatment could open specific niches more favorable to invading pathogens, which then gives rise to the increased susceptibility to bacterial infections seen in IBD/UC patients.
Maintenance of UC requires patients to avoid stress, certain foods, and alcohol, as all three can potentially induce flare periods of UC. 2, 9 Specifically, physicians recommend UC patients maintain a sober lifestyle, 9 but there exists a gap in knowledge as to how alcohol intoxication affects UC flare periods.
Alcohol consumption is well known to be both pro-inflammatory and directly harmful to gut barrier function as it breaks down the normal physical and immunological barrier provided by intestinal epithelial cells and gut associated lymphoid tissue, respectively. [10] [11] [12] [13] Alcohol alone is known to induce intestinal erosion, which can impair intestinal absorption leading to increases in diarrhea and intestinal permeability, allowing for leakage of bacteria or bacterial endotoxins into the circulation. 12, 14, 15 Despite this, only a handful of studies have explored the impact of alcohol in the setting of UC. Some research has shown that alcohol has a deleterious role in UC by increasing gastrointestinal symptoms, 13 inducing a flare 16 and promoting disease onset, 17 while one study describes that alcohol has no effect in the onset of UC. 18 The inconsistency of evidence in either support or contradiction of alcohol's role in exacerbating UC flare and/or onset prompted us first to elucidate whether alcohol is a contributing factor in UC and UC research.
To further address this question, we conducted a retrospective analysis of patient databases to assess clinical outcomes of patients admitted with diagnoses for IBD, UC, and CD that either have or do not have documented history of alcohol use. The results of this analysis suggested that patients with documented history of alcohol use may have an increased risk of infections as well as require more diagnostic and therapeutic procedures.
These findings led us to generate two models that focus on the impact of alcohol in one form of IBD, UC with the hypothesis that not only does alcohol further exacerbate UC flares, but also increases susceptibility of UC patients to bacterial infections. In one model, mice were treated with dextran sulfate sodium (DSS) and a subsequent binge alcohol paradigm, allowing us to examine the ability of alcohol to exacerbate a flare period. In the other model, mice received the combined DSS-induced colitis and binge-alcohol paradigm followed by an inoculation of Citrobacter rodentium (C. rod), which allowed us to understand how alcohol increases susceptibility of UC patients to bacterial infections.
METHODS

Patient database analysis
We obtained data from the Healthcare Cost and Utilization Project Revision, Clinical Modification, (ICD-9-CM) diagnosis codes, we defined three study groups: IBD, UC, and CD. All patient admission data was retained if the patient had a primary diagnosis of IBD. All of the ICD-9-CM codes used in this study can be found in Supplementary Table S1 .
In addition, we utilized the HCUP cost-to-charge ratio files, which provide a ratio of the actual cost relative to the total amount charged to insurance for each separate hospital. These files are used to estimate the actual cost for individual patient admissions.
Comorbidities were assigned to patients on the basis of the Agency for Healthcare Research and Quality (AHRQ) comorbidity measures.
For each individual patient, if the presence of a comorbidity was indicated, then the comorbidity was applied to all of that patient's admissions. Patients were classified as smokers based on whether any admission contained ICD-9-CM codes for tobacco use disorder or personal history of tobacco use. To evaluate the impact of alcohol on outcomes in IBD, patients were identified as having a documented history of alcohol use (+A) based on whether any admission contained ICD-9-CM codes relating to alcohol use or the AHRQ comorbidity measure for alcohol abuse, otherwise the patients were classified as not having a documented history of alcohol use (-A).
Following this, only admissions for which the primary cause was IBD, UC, or CD were retained and all other admissions were excluded.
Patients aged 18-90 years of age were included for study. Admissions missing data elements for the median household income national quartile for patient ZIP code, unique VisitLink patient identifier, age, length of stay, total charges, and patient race, were excluded. The -A and +A patients from each respective study group of IBD, UC or CD, were propensity score matched 1:1 at their first admission based on age, sex, race, primary expected payer, median household income national quartile for patient ZIP code, smoking status, and various comorbidities (AIDS, congestive heart failure, chronic pulmonary disease, coagulopathy, depression, diabetes mellitus, drug abuse, hypertension (combined complicated and uncomplicated), neurological disorders, obesity, psychoses, and renal failure). Subsequent admissions of propensity matched patients following their first recorded hospital admission were collected. The complete admission history of matched patients within each study group was used for data analysis, allowing for a 5 year perspective of what occurs when -A and +A patients are admitted for IBD, UC, or CD. The patient selection workflow is detailed in Fig. S1 .
Secondary diagnoses occurring during admission that were identified by ICD-9-CM codes, included Clostridium difficile infection, poorly defined intestinal infection, and all other intestinal infections, inclusive of C. difficile and poorly defined intestinal infection. Procedures during admission were identified by ICD-9-CM volume 3 and included CT scan of abdomen, small intestine biopsy, small intestine resection, colectomy, large intestine biopsy, rectal biopsy, and antibiotic injection.
Since the patient data within the HCUP SID is de-identified and publically available, the database analysis was exempt from institutional review board approval. 
Induction of DSS colitis
Citrobacter rodentium infection
Mice were subjected to the DSS-induced colitis and binge alcohol paradigm as described above. However, after the last gavage on day 7, mice were further divided into 2 subgroups: mice gavaged with 1 × 
Tissue Staining
For H&E staining, 2 cm of colon tissue closest to the rectum was taken from each mouse and fixed with 10% phosphate buffered formalin. Fixed tissues were then paraffin embedded, sectioned at 5 m, and stained with H&E by AML laboratories (Saint Augustine, Florida).
Images were taken on an Olympus BX43 Microscope using an Olympus DP26 camera.
Histopathology scoring
H&E stained sections were analyzed and scored in a blinded manner by X. D. X. D. is a trained pathologist at Loyola University Chicago and author on this study. Scoring was based on a modified 0-4 point scale examining exudate, epithelial damage, polymorphonuclear leukocyte invasion, and submucosal edema. 19 The values from each of the 4 categories were added to produce a combined histopathology score for each animal.
Colon length and average clinical scores
Immediately following euthanasia, colons were excised and length measured. Baseline clinical scores were determined using a modified protocol from Siegmund et al. 20, 21 Briefly, no weight loss was registered as 0, weight loss of 1-5% from baseline was assigned 1 point; 6-10%, 2 points; 11-20%, 3 points; and more than 20%, 4 points. For stool consistency, 0 points were assigned for well-formed pellets, 2 points for pasty and semiformed stools that did not adhere to the anus, and 4 points for liquid stools that did adhere to the anus. For bleeding, 0 was assigned for no blood by using hemoccult (Beckman Coulter), 2 points for positive hemoccult, and 4 points for gross bleeding.
ELISA
Mice in all 4 groups were sacrificed 3 h after the last gavage on day 7, as seen in 
Statistics
For patient database analysis, we utilized a Student's t-test for mean cost, Mann-Whitney U test for median length of stay with interquartile ranges (IQRs), and 2 test for categorical variables. Statistical analysis and propensity score matching were performed using STATA version 12 (StataCorp LP, College Station, TX). For the mouse model experiments, comparisons within groups were analyzed using a twoWay ANOVA with a Tukey post-hoc test. Analysis was done using GraphPad Prism software. A confidence level of P < 0.05 was considered statistically significant. Significance is represented throughout the manuscript as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Online supplementary material
Supplementary Fig. S1 is a schematic of the patient data selection process. Supplementary Table S1 lists ICD-9 diagnosis codes used to define study populations and the variables examined in the study.
Supplementary Tables S2 and S3 provide patient demographic and comorbidity statistics
RESULTS
Within the patient database study groups, there were 41,810 IBD patients, 18,695 UC patients, and 24,059 CD patients that met the inclusion criteria. The baseline demographics of these groups are shown in Tables 1, 2 Table S3 ).
Post propensity matching, the differences observed for age, sex, race, smoker status, primary expected payer, median household income, and comorbidities between the -A and +A patients within the three study groups were no longer statistically significant (Table 1;   Supplementary Tables S2 and S3 ). For the IBD study group, there were 2,021 matched patients (Table 1) , that encompassed 4,965
IBD-A admissions and 4,013 IBD+A admissions (Table 4 ). For the UC study group, there were 992 matched patients (Table 2) , that encompassed 1,602 UC-A admissions and 1,437 UC+A admissions (Table 4 ). For the CD study group, there were 1,083 matched patients (Table 3) , that encompassed 3,089 CD-A admissions and 2,548 CD+A admissions (Table 4) . Examination of intestinal infection diagnoses during the admission for either the IBD, UC, or CD study groups revealed that +A patients had significantly increased intestinal infections (Table 4 ). The IBD+A patients had increased Clostridium difficile intestinal infection (2% vs.
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2.6%, P < 0.05), poorly defined intestinal infection (0.4% vs. 0.8%, P < 0.01), and overall intestinal infections (2.6% vs. 3.9%, P < 0.01).
The UC+A patients had increased poorly defined intestinal infections (0.6% vs. 1.5%, P < 0.05), while the CD+A patients had increased intestinal infections of all types (2.1% vs. 3.1%, P < 0.05).
With regard to procedures during the admission (Table 4 ), all +A patients had significant increases of abdominal CT scans (IBD: 6.8% vs.
9.6%, P < 0.001; UC: 6.9% vs. 9.0%, P < 0.05; CD: 7.3% vs. 9.9%, P < 0.01) and antibiotic injections (IBD: 3.1% vs. 5.8%, P < 0.001; UC:
3.8% vs. 5.5%, P < 0.05; CD: 3.4% vs. 5.8%, P < 0.001). Large intestine and rectal biopsies were significantly increased in +A patients compared to -A patients within the IBD study group (18.1% vs. 21.7%, P < 0.001; 3.1% vs. 4.3%, P < 0.01). Within the UC and CD study group, large intestine and rectal biopsies were not significantly changed between the -A and +A patients, although UC+A patients did have increased large intestine biopsies (30.7% vs. 32.6%, P = 0.272). Small intestine biopsies were unchanged between the -A and +A patients.
Resection of the small intestine was significantly increased in -A patients with IBD (1.9% vs. 1.1%, P < 0.01) and CD (2.4% vs. 1.5%, P < 0.05). For the UC study group, -A patients displayed a trend toward increased colectomy (4.7% vs. 3.4%, P = 0.077). The differences in percentages of colectomy and small intestine resection procedures for the UC and CD study groups support the appropriate separation of these patients into their respective groups.
The median length of stay was unchanged between -A and +A patients in all study groups (4 days), however the IQR was significantly increased for the -A patients in the IBD (2-7 days vs. 2-6 days, P < 0.01) and CD (2-7 days vs. 2-6 days, P < 0.05) study groups.
In terms of total cost, the -A patients had increased total cost during hospitalization for all study groups compared to the +A patients Colonic inflammation is a hallmark symptom of UC. To further delineate how alcohol could be exacerbating an UC flare, levels of large intestine pro-inflammatory cytokines were determined. We hypothesized that alcohol would further increase levels of large intestine pro-inflammatory cytokines following the addition of our alcohol binge paradigm. Our results revealed that in mice receiving DSS Ethanol, IL-18 ( Fig. 4A) , IL-1 (Fig. 4B) , and KC (Fig. 4E) trended to increase compared to DSS Vehicle treated mice. However, the cytokines, IL-6 (Fig. 4C) , and TNF- (Fig. 4D) were not found to be increased in the colons of DSS Ethanol treated mice compared to mice receiving DSS Vehicle. Although increases in inflammation following DSS Ethanol did not reach statistical significance, total large intestine homogenates were used for all ELISAs, and we anticipate specifically isolating inflamed areas in contrast to diluting inflamed areas with non-inflamed areas (as commonly occurs in the intestines of UC patients) will yield statistical significance. However, future work will focus on this and the specific cell types in the intestine responsible for the increases in inflammation that we do see in the total homogenates.
UC patients are at higher risk of developing bacterial infections. 25, 26 To understand whether consumption of alcohol not only impacts UC patient's increased susceptibility to infection but also increases severity of symptoms related to bacterial infection, we utilized our model of DSS-induced colitis and binge alcohol, as described above, along with a single inoculation of C. rod, a well-known
Gram negative enteropathogen associated with colonic infection, at 1 × 10 5 CFUs 3 h after the last gavage on day 7 (Fig. 5A) . As can be seen Weight loss and gain was also monitored as described previously by percent change from day 0 to day 11 as only 50% of the mice in the DSS Ethanol + C. rod infection group survived till day 11. By day 11
following C. rod infection, mice in the DSS Ethanol group experienced a ∼27% decrease from their original body weight compared to ∼22% in the DSS Vehicle group (Fig. 6A ) giving evidence to our hypothesis of alcohol not only increasing susceptibility to infection with UC, but also increasing severity of symptoms associated with UC and infection.
Increased weight loss accompanied increases in colonic shortening in the DSS Ethanol + C. rod group compared to mice in the DSS Vehicle + C. rod group, Fig. 6B .
Again, to understand differences in histopathology following infection with C. rod, sections of colon were taken closest to the rectum, stained via H&E, blinded, and scored by a pathologist. Figure 7A shows gross differences in large intestine morphology after DSS Ethanol + C.
rod treatment compared to all other groups. As in Fig. 2B , inflammatory infiltrate and epithelial damage were assessed and were severely increased in the DSS Ethanol + C. rod mice compared to that of the DSS Vehicle + C. rod group. The combined histopathology scores in DSS Ethanol + C. rod treated mice were significantly increased compared to mice in the DSS Vehicle + C. rod group, Fig. 7B .
As in Fig. 4 , we assessed colonic inflammation under the hypothesis that C. rod infection would further increase inflammation in mice receiving DSS Ethanol treatment, which could perpetuate increased rod group had increased levels of IL-18 ( Fig. 8A ) and IL-1 (Fig. 8B) compared to DSS Vehicle + C. rod. Furthermore, the pro-inflammatory cytokine IL-6 was increased in both the DSS Ethanol + C. rod and DSS Vehicle + C. rod compared to mice treated with DSS alone (Fig. 8C ).
However, both TNF-and KC were not further increased following C.
rod infection after DSS Ethanol treatment ( Fig. 8D and E).
DISCUSSION
Alcohol is known to have numerous deleterious effects in a variety of settings, yet its effects in IBD are not well understood. In this study, we described a potential role for alcohol affecting the inpatient care of IBD patients as well as prolonging an inflammatory flare period and increasing pathogenic infection in a mouse model of UC.
Research has shown that IBD patients and alcoholic patients carry an intestinal bacterial dysbiosis. 27, 28 A dysbiosis is believed to provide pathogens an opportunity to colonize and proliferate. 29 Indeed, studies have shown IBD patients and alcoholics are at risk for increased infections. 30, 31 Thus, the combination of alcohol use in a patient with IBD would likely lead to an increase in the amount of intestinal infections, which is exactly what we observe in our patient database analysis. Furthermore, the +A patients required increased antibiotic injections as well as increased diagnostic procedures. Despite these increases, the +A patients had decreased total costs compared to -A patients. This can likely be explained by the decrease in surgical procedures (colectomy and small intestine resection) observed in the +A patients. These patients might be less than ideal candidates for surgery, which is often more expensive. In addition, while the median length of stay was unchanged between the -A and +A patients, the IQR for the length of stay was increased for the -A patients, which may also be related to the increase in surgical procedures since surgical patients require longer hospitalization periods post-surgery. How this decrease in surgical interventions affects the clinical course of IBD patients with alcohol use remains to be further elucidated.
We would like to note that to be coded for an ICD-9 diagnosis for an alcohol related disorder, the patient must have had some history of significant alcohol intake, thus our +A study group likely comprises mostly heavy drinkers. Unfortunately, the databases do not contain information regarding the amount of alcohol a patient had prior to an admission. Furthermore, the databases do not contain the exact cause of the IBD admission, thus we cannot discern whether a patient was admitted for a flare or other complication of IBD. Therefore, the findings of this analysis warrant additional research of IBD patients that could provide more detailed information beyond what is available through ICD-9 codes.
Overall, the results of this patient database analysis further support the suggestion that alcohol has some negative impacts on the clinical outcomes of patients with IBD, 13 which led us to examine and characterize the mechanism by which alcohol exacerbates the flare period and infective capacity in a mouse model of DSS-induced colitis.
To our knowledge, this is the first time a murine model of UC and alcohol has been developed to allow a better understanding of how drinking alcohol could affect a patient with UC. Understanding potential environmental factors that could contribute to disease flares, either as a trigger or an exacerbation of symptoms, is critical to improving the quality of life of UC patients stuck in the maintenance of their disease hoping to avoid a flare or a worsening of symptoms during a flare period.
We were able to show that mice undergoing a binge alcohol paradigm following DSS-induced colitis had exacerbated symptoms of UC as shown by increases in weight loss, colon shortening, histopathology and clinical scores, and inflammation, all of which are standard assessment of UC severity in mouse models. Besides symptoms associated with UC itself, UC patients have a higher propensity to other comorbidities such as infection. Hence, we adapted our model of otics is able to inhibit DSS-induced colitis. 39, 40 Additionally, cytokines known to be induced upon AhR activation, specifically IL-22, are known to be up-regulated during remission periods of UC. 41, 42 In the intestine, IL-22 can stimulate proliferation, mucous production, and AMP secretion, which could drive entrance into the remission period from a UC flare. [43] [44] [45] [46] [47] [48] Understanding the interplay between these pathways, UC flare, the gut microbiome, and intestinal inflammation in the context of binge alcohol is critical to the development of a therapeutic intervention that would allow improvements to UC patient's lifestyles especially those stuck in life-long maintenance therapy.
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